[Photographic follow-up of the topical use of prednicarbate preparations in inflammatory dermatoses].
In 20 patients suffering from acute or chronic inflammatory dermatoses, topical treatment with prednicarbate (Dermatop) was photographically documented and evaluated. Because of the rapid and pronounced anti-inflammatory and anti-edematous effect of prednisolone-17-ethyl carbonic ester without halogenic groups, therapy took only 7 to 21 days. Since there was practically no suppression of the endogenic biosynthesis of cortisol and no atrophogenic potency, we expected a minimum of side effects along with a maximum of therapeutic results.
H
H
Schulz
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003872:Dermatitis / Q000188:drug therapy*; D003876:Dermatitis, Atopic / Q000188:drug therapy; D003877:Dermatitis, Contact / Q000188:drug therapy; D004485:Eczema / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D011239:Prednisolone; C035287:prednicarbate
Fotografische Verlaufskontrolle nach topischer Anwendung von Prednicarbat-Zubereitungen bei entzündlichen Dermatosen.